Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selective Intra-Arterial Hypothermia Combined With Endovascular Treatment for Acute Basilar Artery Occlusion (CHILL- BAO): A Multicenter, Prospective, Open-Label, Blinded-Endpoint, Randomized Controlled Trial

NCT07896655 is registered in ClinicalTrials.gov with Guangdong Second Provincial General Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07896655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Selective Intra-Arterial Hypothermia Combined With Endovascular Treatment for Acute Basilar Artery Occlusion (CHILL- BAO): A Multicenter, Prospective, Open-Label, Blinded-Endpoint, Randomized Controlled Trial
Lead sponsor
Guangdong Second Provincial General Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
March 31, 2030
Enrollment
818 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke, basilar artery occlusion

Arms

As registered; 2 arms.

  • Hypothermia group Experimental4°C saline infusion, Mechanical thrombectomy

    Following successful reperfusion with endovascular treatment (EVT), participants in the hypothermia group will receive a selective intra-arterial infusion of 350 mL of 4°C normal saline at a fixed rate of 30 mL/min. No dose escalation will be performed.

  • Normothermia group Active comparatorMechanical thrombectomy, Normothermic saline infusion

    Receive a total of 350 ml of room temperature (22-25°C) saline infusion based on EVT treatment; the infusion rate is the same as that of the hypothermia group

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Distribution of Modified Rankin Scale Scores at 90 Days 90 (±7) days after randomization

    The distribution of modified Rankin Scale (mRS) scores at 90 (±7) days after randomization will be assessed across all seven categories (0-6) using a shift analysis. Scores range from 0 (no symptoms) to 6 (death); lower scores indicate less disability.

Lead sponsor's other trials

Guangdong Second Provincial General Hospital, most recent start first.

Similar trials

Same condition (Ischemic Stroke) and phase, most recent start first.